Literature DB >> 15272896

CSF isoelectrofocusing in a large cohort of MS and other neurological diseases.

A Bourahoui1, J De Seze, R Guttierez, B Onraed, B Hennache, D Ferriby, T Stojkovic, P Vermersch.   

Abstract

The present study was performed in order to confirm the diagnostic value of isoelectrofocusing (IEF) in a large multiple sclerosis (MS) cohort and to evaluate the various neurological diseases probably to present a similar IEF profile. The cerebrospinal fluid (CSF) of 1292 patients with neurological diseases was studied by IEF. After a follow-up of 2-36 months, we only included patients with a definite MS or confirmed diagnosis of other neurological diseases (OND). MS was diagnosed in 407 patients and OND in 593 patients. For patients in whom three or more oligoclonal bands (OCB) were detected, IEF results showed a sensitivity of 85% and a specificity of 92% for the diagnosis of MS. The positive and negative predictive values were 86.5 and 90%, respectively. Inflammatory and infectious disorders of the central nervous system represented the main affections associated with OCB, including human immunodeficiency virus encephalitis, Lyme disease and less frequently Sjogren syndrome. Furthermore, when OCB were observed, 10 or more bands were more frequently found in MS than in OND (P < 0.0001). IEF of the CSF is a reliable method for the diagnosis of MS. The absolute number of bands may help to discriminate between MS and OND.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15272896     DOI: 10.1111/j.1468-1331.2004.00822.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  9 in total

1.  High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis.

Authors:  Simon Gamraoui; Guillaume Mathey; Marc Debouverie; Catherine Malaplate; René Anxionnat; Francis Guillemin; Jonathan Epstein
Journal:  J Neurol       Date:  2019-02-01       Impact factor: 4.849

2.  The presence of oligoclonal IgG bands in human CSF during the course of neurological diseases.

Authors:  M Haertle; U Kallweit; M Weller; M Linnebank
Journal:  J Neurol       Date:  2014-01-22       Impact factor: 4.849

3.  Comparisons of presentations and outcomes of neuromyelitis optica patients with and without Sjögren's syndrome.

Authors:  Yu Hua Zhong; Zhi Gang Zhong; Zhou Zhou; Zhen Yu Ma; Meng Yao Qiu; Fu Hua Peng; Wei Xi Zhang
Journal:  Neurol Sci       Date:  2016-11-05       Impact factor: 3.307

4.  Neurological Disorders in Primary Sjögren's Syndrome.

Authors:  Gabriel J Tobón; Jacques-Olivier Pers; Valérie Devauchelle-Pensec; Pierre Youinou
Journal:  Autoimmune Dis       Date:  2012-03-05

5.  The Persisting Significance of Oligoclonal Bands in the Dawning Era of Kappa Free Light Chains for the Diagnosis of Multiple Sclerosis.

Authors:  Philipp Schwenkenbecher; Franz Felix Konen; Ulrich Wurster; Konstantin Fritz Jendretzky; Stefan Gingele; Kurt-Wolfram Sühs; Refik Pul; Torsten Witte; Martin Stangel; Thomas Skripuletz
Journal:  Int J Mol Sci       Date:  2018-11-29       Impact factor: 5.923

Review 6.  The Cerebrospinal Fluid in Multiple Sclerosis.

Authors:  Florian Deisenhammer; Henrik Zetterberg; Brit Fitzner; Uwe K Zettl
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

7.  The clinical significance of single or double bands in cerebrospinal fluid isoelectric focusing. A retrospective study and systematic review.

Authors:  Harald Hegen; Anne Zinganell; Michael Auer; Florian Deisenhammer
Journal:  PLoS One       Date:  2019-04-15       Impact factor: 3.240

Review 8.  Neurology of rheumatologic disorders.

Authors:  Amre Nouh; Olimpia Carbunar; Sean Ruland
Journal:  Curr Neurol Neurosci Rep       Date:  2014-07       Impact factor: 6.030

9.  Cerebrospinal fluid humoral immunity in the differential diagnosis of multiple sclerosis.

Authors:  Evanthia Bernitsas; Omar Khan; Sara Razmjou; Alexandros Tselis; Fen Bao; Christina Caon; Scott Millis; Navid Seraji-Bozorgzad
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.